Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a Boston-based synthetic biology company that entered the public markets in 2021 through a merger with Soaring Eagle Acquisition Corp. (SRNG), a blank-check vehicle sponsored by Eagle Equity Partners, the team led by Harry Sloan, Jeff Sagansky, and Eli Baker. Operating in the biotechnology and life sciences sector, Ginkgo built its business around a cell-programming platform designed to enable customers across pharma, agriculture, and industrial applications to engineer organisms at scale. The company filed an 8-K current report with the SEC on July 30, 2026, under accession number 0001628280-26-051041. Sign up for a free SpacDesk account to access the full filing detail, historical SPAC merger data, and real-time alerts on DNA and hundreds of other de-SPAC companies.